Related Experiment Video
Updated: Sep 11, 2025

04:25
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
9.9K
LncSNHGs: new targets in osteosarcoma
Yining Zhang1,2, Jinfa Wu1,3, Jiaming Liu4,5
1Department of Orthopaedic Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, PR China.
Cancer Gene Therapy
|August 16, 2025
Summary
Long non-coding RNAs (lncRNAs) in small nucleolar RNA host genes (SNHGs) are crucial in osteosarcoma (OS) development. Dysregulated SNHG expression impacts tumor growth, metastasis, and treatment, offering new diagnostic and therapeutic targets for OS.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Long non-coding RNAs (lncRNAs) are key regulators in cancer biology.
- Osteosarcoma (OS) is a primary bone malignancy with complex genetic underpinnings.
- Small nucleolar RNA host genes (SNHGs) are a lncRNA family implicated in various cancers.
Purpose of the Study:
- To provide a comprehensive review of the lncRNA SNHG family in osteosarcoma.
- To elucidate the biological roles and molecular mechanisms of SNHGs in OS.
- To summarize expression patterns and clinical relevance of SNHGs in OS.
Main Methods:
- Literature review and analysis of existing studies on SNHGs in osteosarcoma.
- Examination of molecular mechanisms underlying SNHG functions in OS.
- Synthesis of data on SNHG expression and its correlation with OS progression.
Main Results:
- SNHG family members show altered expression in osteosarcoma tissues.
- Dysregulated SNHGs influence critical oncogenic processes like proliferation, metastasis, and apoptosis.
- SNHGs are implicated in chemoresistance and autophagy modulation in OS.
Conclusions:
- The lncRNA SNHG family represents a significant area of research in osteosarcoma.
- SNHGs play multifaceted roles in OS pathogenesis, affecting tumor growth and treatment response.
- Targeting SNHGs may offer novel diagnostic, prognostic, and therapeutic strategies for osteosarcoma.
Related Concept Videos
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

